BioAge Labs
BIOA | NASDAQ
$5.22
-$0.33 (-5.95%)
At close: Nov 16, 2026, 4:00 PM ET
$5.21
-$0.01 (-0.19%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-5.95%
(1D)No price chart data available for 1D timeframe.
Rating
38
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #580/1021 (Top 57%)
Key Statistics
Market Data
Market Cap $239.66M
1D Range
5.08 5.64
52W Range
4.84 25.10
Valuation (TTM)
PE -2.05
PB 0.69
EV/EBITDA 0.37
Valuation (NTM)
Forward PE N/A
Forward PEG -0.15
Price Target $21.00
Cash Flow
FCF Yield -43.0%
SBC Adj. FCF Yield -49.6%
SBC Impact -15.4%
Margins
Gross Margin 99.3%
Operating Margin -1401.8%
FCF Margin -1197.8%
Growth (CAGR)
Revenue 3Y | 5Y 88.9% |
N/A
Dil EPS 3Y | 5Y -10.7% |
N/A
FCF 3Y | 5Y -33.0% |
N/A
Returns
ROA -29.3%
ROE -31.4%
ROIC -34.5%
Financial Health
Net Cash
$280.91M
Current Ratio 15.51
Interest Coverage -913.20
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that ...
Sector Healthcare
Industry Biotechnology
Employees 61
IPO Date Sep 26, 2024
Website bioagelabs.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.73
Miss -7.35%
YoY:
-30.36% REV
$298K
Miss -79.83%
YoY:
-85.49%Next Earnings
Mar 23, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
7
Consensus
Buy
Price Target
$21.00
Upside
+302.30%
Buy (6)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove BIOA